Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

OMS103HP

Other · developed by Omeros

Phase 3 Most advanced trial (none active)

OMER Developer

1 Registered trials

What is OMS103HP?

OMS103HP is an irrigation solution used during a procedure on the knee.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Musculoskeletal
Developer: Omeros Corporation (OMER)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00226772	Phase 3	Knee Injuries	Completed	OMER

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Knee Injuries

More from Omeros

Narsoplimab FDA approved OMS103HP-S Phase 3 OMS201 Phase 1/2 OMS643762 Phase 2 Zaltenibart Phase 2

Sources

ClinicalTrials.gov NCT00226772

Updated Oct 11, 2026. Something wrong or missing? Report it on the OMER page.

Follow OMER, the company behind OMS103HP

See OMER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OMER catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z